Skip to search formSkip to main contentSkip to account menu

PF-06463922

Known as: ALK/ROS1 Inhibitor PF-06463922, PF06463922 
An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
We shall overcome (drug resistance) some day
The discovery of the involvement of defined molecular pathway(s) in tumor development and therapeutic targeting of such pathway(s… 
2018
2018
Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations
The c-ros oncogene 1 (ROS1) has proven to be an important cancer target for the treatment of various human cancers. The… 
2016
2016
Abstract B12: The ALK inhibitor PF-06463922 shows significant response as a single agent in ALK/MYCN driven models of neuroblastoma
ALK inhibitors such as the ALK/MET/ROS1 inhibitor crizotinib (Xalkori) have shown clinical efficacy in a number of tumour types… 
2015
2015
Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.
8018 Background: Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) fusions define 2 molecular subsets of patients (pts… 
2015
2015
Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.
TPS2620 Background: Lung cancer is the most common cancer worldwide, with non-small cell lung cancer (NSCLC) occurring in 85% of… 
Review
2015
Review
2015
Anaplastic Lymphoma Kinase as a Therapeutic Target in Non–Small Cell Lung Cancer
AbstractThe therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK… 
2015
2015
Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models
Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor of ALK, ROS1 and c-MET that is approved in over 70… 
2015
2015
Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma
Neuroblastomas (NBs) harboring activating point mutations in the kinase domain of anaplastic lymphoma kinase (ALK) are… 
2015
2015
Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Overcoming resistance to targeted kinase… 
2015
2015
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors
Rearranged or mutated forms of the Anaplastic Lymphoma Kinase (ALK) are involved in the pathogenesis of various cancers, in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)